Insider Monkey - 2025-05-29 04:31
SCYNEXIS, Inc. (NASDAQ:SCYX) has officially restarted patient dosing in its Phase III MARIO trial for Brexafemme (ibrexafungerp) after the FDA lifted a nearly two-year clinical hold. The hold, initiated over concerns of beta-lactam contamination at the original manufacturing facility, was removed once new drug batches were produced at a separate location. With trial sites now […]
